Channing Der, PhD
Sarah Graham Kenan Distinguished Professor
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Channing J. Der, PhD is currently Sarah Graham Kenan Distinguished Professor of Pharmacology at the University of North Carolina at Chapel Hill. He received his PhD from the University of California, Irvine and he then completed his postdoctoral studies at Harvard Medical School and the Dana-Farber Cancer Institute. His research has centered on the study of the RAS oncogene and the RAS superfamily and their roles in signal transduction and cancer. His has been funded by grants from the National Cancer Institute, the Lustgarten Foundation, and the Pancreatic Cancer Action Network-AACR. He has authored over 330 publications and is the holder of six patents. He has mentored over 50 past/present postdoctoral fellows and over 30 past/present graduate students. He is currently a member of the NCI Board of Scientific Counselors and the NCI RAS Working Group. He is currently on the scientific advisory boards of the Pancreatic Cancer Action Network, Warp Drive Bio and Mirati Therapeutics. He has served on numerous editorial boards that include Science Signaling and Cancer Research. He has served as a consultant for numerous pharmaceutical companies that include Astra-Zeneca, Novartis, Eli Lilly, Merck and Astex. He is current board member and past president of the Cancer Biology and Training Consortium. His honors include being the recipient of the Hyman L. Battle Distinguished Cancer Research Award and the University of California, Irvine Distinguished Alumnus Award.